Abstract
Background
A test that helps predict the time to the final menstrual period (FMP) has been sought for many years.
Objective
To assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP.
Design
Prospective longitudinal cohort study.
Setting
The Study of Women’s Health Across the Nation.
Participants and Measurements
AMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL.
Main Outcome Measure
Areas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed.
Results
AUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h<48 years of age to 79% at ≥51 years. The probability that a woman with an AMH >100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old.
Conclusions
AMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.
Urinary phthalate metabolite concentrations and serum hormone levels in pre- and perimenopausal women from the Midlife Women’s Health Study
